Conference on Cell Therapies and Bioengineering

September 20-22, 2018
Add to Calendar

We are excited to present the first conference on Cell Therapies and Bioengineering. This conference will highlight new and upcoming research in this field such as CAR T cell therapies, TCR T cells, Immune cells other than conventional T cells, challenges and opportunities for cell therapies for solid tumors, synthetic biology for cellular immunotherapy, and many more! Stay tuned for registration to open shortly!


Abstract Submissions are open until July 20th, 2018

Submit an Abstract

Poster size: 30"x40" any orientation (portrait, or landscape)

Keynote Speakers:

Invited Speakers:

Session Topics:

1. CD19 Story: What Has Worked, and Lessons Learned From the Success of CAR T cell Therapy

2. Challenges and Opportunities for Cell Therapies for Solid Tumors

            a. Antigens

            b. Metabolism

            c. The Tumor Microenvironment

3. Genome Editing for Therapeutic Cell Engineering: Efficacy vs Safety

4. Manufacturing Challenges and “off-the-shelf” Therapies

5. Immunotherapy: Immune Cells other than Conventional T cells

6. Synthetic Biology for Cellular Immunotherapy

7. Novel Delivery Technology for Cell Therapies

8. Biomarker Analysis and Applications for Cell Therapies

9. TCR T cells

10. Regulatory Aspects of Cellular Therapy Products

11. Understanding and Engineering Persistence

Conference Co-Chairs:

  • Navin Varadarajan, University of Houston
  • Pin Wang, University of Southern California

Organizing Committee:

  • Wilson Wong, Boston University
  • Cameron Turtle, Fred Hutchinson Cancer Research Center
  • Yvonne Chen, University of California, Los Angeles
  • Helen Heslop, Baylor College of Medicine
  • Gianpietro Dotti, University of North Carolina
  • Darrell Irvine, Massachusetts Institute of Technology
  • Velia Siciliano, Synthetic and Systems Biology for Biomedicine, Genova

Featured Speakers

Adrian Bot

Dr. Adrian Bot, M.D., Ph.D. served as a Vice President of Translation Medicine at Kite Pharma, Inc. until October 2, 2017. Dr. Bot served as a Vice President of Scientific Affairs at Kite Pharma, Inc. and served as its Chief Scientific officer.Read more

Timothy Lu

Timothy K. Lu, M.D., Ph.D. is an Assistant Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and Department of Biological Engineering at MIT. Tim has pioneered new approaches to combat infectious diseases with synthetic biology, encode memory in the DNA of living cells, and perform both digital and analog computation in biological systems. Read more

Alexander Marson

Alex Marson completed medical school at Harvard, PhD training at the Whitehead Institute/MIT with Richard Young and Rudolf Jaenisch, Internal Medicine residency at the Brigham and Women’s and clinical training in Infectious Diseases at UCSF. Read more

Kole Roybal

Dr. Roybal is an Assistant Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He is a full member of the Parker Institute for Cancer Immunotherapy and an inaugural Chan Zuckerberg Biohub investigator. Read more

Matthias Stephan

Dr. Stephan’s laboratory in the Clinical Research Division at Fred Hutchinson Cancer Research Center works at the interface of materials science and immunology, designing synthetic materials that can be used as components of novel cancer immunotherapies.Read more

Li Tang

Dr. Li Tang is currently an Assistant Professor and Principal Investigator for the Laboratory of Biomaterials for Immunoengineering (LBI) at École polytechnique fédérale de Lausanne (EPFL). Dr. Li Tang was an Irvington Postdoctoral Fellow in Dr. Darrell Irvine’s lab at MIT.Read more